HAEMONETICS CORP — Director's Dealing 2013

Nov 13, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-11-11

Reporting Person: Kelly Michael P (President, Global Markets)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-11-11	Common Stock	M	9836.0	$39.055	Acquired	20823	Direct
2013-11-11	Common Stock	S	9836.0	$39.7009	Disposed	10987	Direct
2013-11-11	Common Stock	M	18660.0	$30.67	Acquired	29647	Direct
2013-11-11	Common Stock	S	18660.0	$39.7009	Disposed	10987	Direct
2013-11-11	Common Stock	M	30104.0	$27.485	Acquired	41091	Direct
2013-11-11	Common Stock	S	30104.0	$39.7009	Disposed	10987	Direct
2013-11-12	Common Stock	M	2800.0	$27.485	Acquired	13787	Direct
2013-11-12	Common Stock	S	2800.0	$39.6611	Disposed	10987	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-11	Non-Qualified Stock Option (right to buy)	$27.485	M	30104.0	Disposed	2017-07-28	Common Stock (30104)	Direct
2013-11-12	Non-Qualified Stock Option (right to buy)	$27.485	M	2800.0	Disposed	2017-07-28	Common Stock (2800)	Direct
2013-11-11	Non-Qualified Stock Option (right to buy)	$30.67	M	18660.0	Disposed	2018-10-25	Common Stock (18660)	Direct
2013-11-11	Non-Qualified Stock Option (right to buy)	$39.055	M	9836.0	Disposed	2019-10-24	Common Stock (9836)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Performance Shares	$0.0	2027-03-31	Common Stock (25000)	25000	Direct

Footnotes

F1: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

F2: Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).